Article
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
The oncologist - 4 Nov 2024
Morgenstern-Kaplan Dan, Kareff Samuel A, Trabolsi Asaad, Rodriguez Estelamari, Krause Harris, Ribeiro Jennifer R, Tan Heng, Antonarakis Emmanuel S, Lou Emil, Nagasaka Misako, Algaze Sandra, Lenz Heinz-Josef, Liu Stephen V, Halmos Balazs, Hoon Dave S B, Seeber Andreas, Ma Patrick C, El-Deiry Wafik S, Vanderwalde Ari M, Lopes Gilberto
Abstract excerpt
BACKGROUND: TROP2 (TACSTD2) expression is associated with decreased overall survival (OS) in some solid tumors, and the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan has been approved in breast and urothelial carcinomas. We aimed to explore the multi-omic landscape associated with TACSTD2 gene expression in various solid tumors to identify patients most likely to benefit from this approach....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.